Kentucky Medical Cannabis Qualifying Conditions Expansion 2026
This digest highlights the Kentucky medical cannabis qualifying conditions expansion in 2026, detailing 15 new conditions added. Clinicians should monitor these changes for clinical relevance and patient care. The expansion reflects ongoing state-level…
Gov. Beshear expands medical cannabis access, adding 15 new qualifying conditions
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Understanding Your Endocannabinoid System Through Scientific Research
Understanding the endocannabinoid system requires examining peer-reviewed scientific research rather than dismissing cannabis medicine entirely. Dr. Benjamin Caplan leads evidence-based cannabis care at CED Clinic, focusing on how endocannabinoid system…
Why some people may feel hungry after smoking weed – K24 Digital
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Left Exit 12 Off Ramp – CED Clinic
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Cannabis Drug Interaction Check (Free) – Green Bridge Society
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Synthetic Cannabinoids Schedule I Updates 2026: Regulatory Watch
This policy watch highlights synthetic cannabinoids Schedule I updates 2026 with significant clinical and regulatory implications. The DEA's recent actions classify several synthetic cannabinoids as Schedule I substances, affecting clinicians and…
THC Blood-Brain Barrier: Your Endocannabinoid System Waits Patiently
Your endocannabinoid system demonstrates remarkable patience while waiting for THC to cross the blood-brain barrier. Understanding this process helps explain why cannabis effects take time to manifest. This biological masterclass reveals the intricate…
Schedules of Controlled Substances Placement June 02 2026 Updates
The schedules of controlled substances placement June 02 2026 report covers 20 regulatory updates affecting synthetic cannabinoids and opioids. These placements impact clinical research and patient care. Clinicians should stay informed on these…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…
